Potent and selective adenosine A2A receptor antagonists: [1,2,4]-triazolo[4,3-c]pyrimidin-3-ones
Joel M. Harris(University of Utah), Andrew W. Stamford(Merck & Co., Inc., Rahway, NJ, USA (United States)), Geoff Varty(Merck & Co., Inc., Rahway, NJ, USA (United States)), Hongtao Zhang(Chinese Academy of Sciences), Jinsong Hao, Jean E. Lachowicz, Bernard R. Neustadt, Mary Cohen-Williams
Cited by 20
Related Papers
National Survey of Drug-Resistant Tuberculosis in China
|New England Journal of Medicine|2012|649
ErbB receptors: from oncogenes to targeted cancer therapies
|Journal of Clinical Investigation|2007|578
Advances in clinical immunotherapy for gastric cancer
|Biochimica et Biophysica Acta (BBA) - Reviews on Cancer|2021|435
The BACE1 inhibitor verubecestat (MK-8931) reduces CNS β-amyloid in animal models and in Alzheimer’s disease patients
|Science Translational Medicine|2016|416